| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||
Research and development revenue | ||||||||
1,593 | 1,681 | 1,934 | 1,743 | 1,513 | 1,295 | 0 | 0 | 0 |
Costs and expenses: | ||||||||
Costs of research and development revenue | ||||||||
1,409 | 1,459 | 1,542 | 1,401 | 1,208 | 1,027 | 0 | 0 | 0 |
Research and development | ||||||||
3,150 | 3,087 | 2,798 | 2,434 | 2,217 | 2,101 | 0 | 0 | 0 |
Research and development - related party | ||||||||
500 | 900 | 959 | 1,159 | 1,200 | 1,200 | 0 | 0 | 0 |
General and administrative | ||||||||
5,745 | 5,519 | 5,639 | 5,606 | 4,657 | 4,522 | 0 | 0 | 0 |
Foreign currency exchange loss (gain), net | ||||||||
0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 |
Total costs and expenses | ||||||||
10,817 | 10,963 | 11,046 | 10,692 | 9,317 | 8,887 | 0 | 0 | 0 |
Loss from operations | ||||||||
-9,223 | -9,282 | -9,111 | -8,949 | -7,804 | -7,592 | 0 | 0 | 0 |
Interest income | ||||||||
886 | 984 | 1,024 | 1,021 | 975 | 894 | 0 | 0 | 0 |
Loss before income taxes | ||||||||
-8,337 | -8,297 | -8,087 | -7,928 | -6,828 | -6,697 | 0 | 0 | 0 |
Provision for income taxes | ||||||||
9 | 10 | -1,005 | -1,005 | -1,005 | -1,006 | 0 | 0 | 0 |
Net loss | ||||||||
-8,346 | -8,307 | -7,081 | -6,922 | -5,823 | -5,691 | 0 | 0 | 0 |
Basic and diluted net loss per common share (USD per share) | ||||||||
-0.08 | -0.07 | -0.06 | -0.10 | -0.08 | -0.02 | -0.06 | -0.06 | -0.07 |
Basic and diluted weighted-average common shares outstanding (in shares) | ||||||||
27,452 | 27,291 | 27,181 | 26,828 | 26,713 | 26,698 | 27,774 | 28,060 | 28,159 |